BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15645126)

  • 1. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
    Tentori L; Leonetti C; Scarsella M; Vergati M; Xu W; Calvin D; Morgan L; Tang Z; Woznizk K; Alemu C; Hoover R; Lapidus R; Zhang J; Graziani G
    Int J Oncol; 2005 Feb; 26(2):415-22. PubMed ID: 15645126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
    Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
    Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
    Tentori L; Leonetti C; Scarsella M; Muzi A; Vergati M; Forini O; Lacal PM; Ruffini F; Gold B; Li W; Zhang J; Graziani G
    Eur J Cancer; 2005 Dec; 41(18):2948-57. PubMed ID: 16288862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
    Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
    Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
    Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
    FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
    Palma JP; Rodriguez LE; Bontcheva-Diaz VD; Bouska JJ; Bukofzer G; Colon-Lopez M; Guan R; Jarvis K; Johnson EF; Klinghofer V; Liu X; Olson A; Saltarelli MJ; Shi Y; Stavropoulos JA; Zhu GD; Penning TD; Luo Y; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
    Anticancer Res; 2008; 28(5A):2625-35. PubMed ID: 19035287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
    Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
    Tentori L; Portarena I; Barbarino M; Balduzzi A; Levati L; Vergati M; Biroccio A; Gold B; Lombardi ML; Graziani G
    Mol Pharmacol; 2003 Jan; 63(1):192-202. PubMed ID: 12488552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
    Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
    Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
    Toshimitsu H; Yoshimoto Y; Augustine CK; Padussis JC; Yoo JS; Angelica Selim M; Pruitt SK; Friedman HS; Ali-Osman F; Tyler DS
    Ann Surg Oncol; 2010 Aug; 17(8):2247-54. PubMed ID: 20182810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
    Tentori L; Dorio AS; Mazzon E; Muzi A; Sau A; Cuzzocrea S; Vernole P; Federici G; Caccuri AM; Graziani G
    Eur J Cancer; 2011 May; 47(8):1219-30. PubMed ID: 21269821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
    Tong Y; Bouska JJ; Ellis PA; Johnson EF; Leverson J; Liu X; Marcotte PA; Olson AM; Osterling DJ; Przytulinska M; Rodriguez LE; Shi Y; Soni N; Stavropoulos J; Thomas S; Donawho CK; Frost DJ; Luo Y; Giranda VL; Penning TD
    J Med Chem; 2009 Nov; 52(21):6803-13. PubMed ID: 19888760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
    Penning TD; Zhu GD; Gong J; Thomas S; Gandhi VB; Liu X; Shi Y; Klinghofer V; Johnson EF; Park CH; Fry EH; Donawho CK; Frost DJ; Buchanan FG; Bukofzer GT; Rodriguez LE; Bontcheva-Diaz V; Bouska JJ; Osterling DJ; Olson AM; Marsh KC; Luo Y; Giranda VL
    J Med Chem; 2010 Apr; 53(8):3142-53. PubMed ID: 20337371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
    Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
    Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
    Penning TD; Zhu GD; Gandhi VB; Gong J; Liu X; Shi Y; Klinghofer V; Johnson EF; Donawho CK; Frost DJ; Bontcheva-Diaz V; Bouska JJ; Osterling DJ; Olson AM; Marsh KC; Luo Y; Giranda VL
    J Med Chem; 2009 Jan; 52(2):514-23. PubMed ID: 19143569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
    Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
    Simbulan-Rosenthal CM; Rosenthal DS; Luo R; Li JH; Zhang J; Smulson ME
    Nucleic Acids Res; 2001 Feb; 29(3):841-9. PubMed ID: 11160908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.